The initial approval by the U.S. Food and Drug Administration (FDA) in 1986 encompassed the following indications: *Uncomplicated urinary tract infections (including cystitis) *Complicated urinary tract infections (restricted use) *Uncomplicated urethral and cervical gonorrhea (however this indication is no longer considered to be effective by some experts due to bacterial resistance) *Prostatitis due to Escherichia coli. *Syphilis treatment:<unk>  has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. Although fluoroquinolones are sometimes used to treat typhoid and paratyphoid fever,<unk>  had more clinical failures than the other fluoroquinolones (417 participants, 5 trials). In ophthalmology,<unk>  licensed use is limited to the treatment of conjunctival infections caused by susceptible bacteria.<unk>  has been restricted in the Republic of Ireland due to the risks of C. difficile super infections and permanent nerve as well as tendon injuries. It licensed use in acute and chronic complicated kidney infections has been withdrawn as a result. The European Medicines Agency, also in 2008, had recommended restricting the use of oral<unk>  to treat urinary infections. CHMP had concluded that the marketing authorizations for<unk> , when used in the treatment of acute or chronic complicated pyelonephritis, should be withdrawn because the benefits do not outweigh their risks in this indication. CHMP stated that doctors should not prescribe oral<unk>  for complicated pyelonephritis and should consider switching patients already taking oral<unk>  for this type of infection to an alternative antibiotic.<unk>  is used for prevention of spontaneous bacterial peritonitis in cirrhotic patients who have a low ascites fluid protein level, impaired renal function, severe liver disease, have had a prior episode of spontaneous bacterial peritonitis, or esophageal variceal bleeding. Note:<unk>  may be licensed for other uses, or restricted, by the various regulatory agencies worldwide.
Norfloxacin
Ofloxacin
Sparfloxacin
Enrofloxacin
Ciprofloxacin
Meropenem
Metronidazole
Cethromycin